Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Catabolism is a fundamental metabolic process that involves the breakdown of complex molecules into simpler units, typically releasing energy in the process. This energy, often in the form of ATP, is essential for various cellular functions, and the smaller molecules produced serve as building blocks for other synthetic processes. Examples of catabolic processes include the breakdown of carbohydrates, proteins, and fats. While catabolism is vital for life, its dysregulation is implicated in numerous diseases, including type II diabetes, metabolic syndrome, cancer, and conditions characterized by excessive tissue wasting like the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS). Catabolism itself is a broad biological process, not a single molecular target like a receptor or enzyme. Therefore, drugs do not 'target' catabolism directly, but rather modulate specific enzymes or pathways within catabolic networks to influence the overall process. Modulating these pathways can have significant therapeutic implications, but also carries potential safety concerns due to the fundamental role of catabolism in maintaining cellular homeostasis and energy balance.
Drugs do not directly target 'Catabolism' as a single entity, but rather modulate specific enzymes or pathways involved in catabolic processes. For example, Etomoxir inhibits carnitine palmitoyltransferase 1 (CPT1), an enzyme crucial for lipid catabolism. Orlistat blocks lipid synthesis and lipolysis. Anabolic steroids like oxandrolone exert anti-catabolic effects by decreasing protein degradation and increasing protein synthesis. Hormones such as cortisol, glucagon, and adrenaline are naturally occurring catabolic agents that stimulate various breakdown processes. Anti-inflammatory agents like anakinra and tocilizumab can indirectly alleviate hypercatabolic states by reducing systemic inflammation. Propranolol, a beta-adrenergic receptor blocker, can inhibit lipolysis and improve protein synthesis.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Catabolism.